We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

The Efficacy of Zidovudine Is Time Limited-Reply

Jens D. Lundgren, MD, DMSc; Court Pedersen, MD, DMSc; Jens Ole Nielsen, MD, DMSc; Andrew N. Phillips, PhD
JAMA. 1994;272(13):1001-1002. doi:10.1001/jama.1994.03520130035019.
Text Size: A A A
Published online


In Reply.  —We appreciate the interest in the results presented in our recent publication. Drs Berman and Wenglin are correct in their interpretation of our results insofar as zidovudine seems to have a beneficial influence on survival when it is initiated in patients with advanced human immunodeficiency virus (HIV) infection. As also pointed out in the "Comment" section of our article, the results agree with the only placebo-controlled study1 and several observational studies2 in patient groups with similar advanced HIV infection as in our population (ie, a survival benefit within the first months after starting zidovudine). However, because of the large number of patients studied, we were also able to suggest whether the effect persisted for extended periods of time; we found this not to be true. Whether optimal dosage and combination antiretroviral therapy will eventually affect survival of AIDS patients, as suggested by Berman and Wenglin, awaits


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.